GSK, Eon settle Wellbutrin SR dispute
Executive Summary
GlaxoSmithKline and Eon reach settlement in Wellbutrin SR patent lawsuit. Agreement was reached before a Manhattan federal judge ruled on GSK's infringement claims. An appeals court ruled in a separate case that Impax' generic bupropion sustained-release does not infringe GSK's patent. The Eon case involved similar issues, and the settlement is effective if the Impax ruling is not reversed on appeal. Eon launched its generic "at risk" Jan. 15; Watson and Impax/Teva subsequently entered the market (1"The Pink Sheet" March 29, 2004, p. 27)...